Skip to content Carb-X
Carb-X
Boston University
Mobile Menu Toggle navigation
  • Sign Up
  • Contact
  • Twitter
  • LinkedIn
Carb-X
Boston University
Boston University
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Board
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University School of Law
  • Portfolio
    • Portfolio Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
    • Comprehensive Support
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Funding Themes
    • Application Process
    • Entering Portfolio
    • Apply Here
    • Omnibus Outcomes
  • Resources
    • CARB-X Connect
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
    • Fact Sheets
    • AMR Test Directory
    • Research Compliance
  • News
    • CARB-X News
    • Recommended News
    • In the News
    • Antibiotic Resistance
    • Product Developer News
  • Events
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Board
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University School of Law
  • Portfolio
    • Portfolio Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
    • Comprehensive Support
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Funding Themes
    • 2024 Solicitation
    • Application Process
    • Entering Portfolio
  • Resources
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
    • Fact Sheets
    • AMR Test Directory
  • News
    • CARB-X News
    • Recommended News
    • In the News
    • Antibiotic Resistance
    • Product Developer News
  • Events
  • Contact
  • Legal

Portfolio Company

  • Portfolio
  • >
  • Gallery
Vedanta Biosciences

VEDANTA BIOSCIENCES    Cambridge, MA, USA
vedantabio.com

VE303
MICROBIOME

Direct-Acting Microbiome-based Therapeutic
Vedanta Biosciences is developing a novel class of therapies based on rationally-defined consortia of bacteria derived from the human microbiome. Focused on addressing immune and infectious diseases, Vedanta Biosciences is a leader in the microbiome field with capabilities and deep expertise to discover, develop, and manufacture medicines based on live bacterial consortia. Vedanta’s lead program, VE303, is a rationally-defined bacterial consortia that colonizes the gut and safely outcompetes C. difficile, while reconstituting gut microbiota previously disrupted by antibiotic treatment. As a part of the CARB-X program, Vedanta will progress VE303 through the completion of Phase 1 clinical trials. Vedanta Biosciences is an affiliate of PureTech Health.

Current Development Stage: Phase I

CARB-X Investment: Initial investment of up to $5.4m.

Initial CARB-X Investment Date: October 1, 2017

Graduation Date: September 30, 2018

Read their Spotlight on Science 1 and Spotlight on Science 2

Carb-X

Led by Boston University

Copyright 2025

  • Contact
  • Careers
  • Site Credits
  • Legal
  • Twitter
  • LinkedIn

Copyright 2025

We use cookies to ensure that we give you the best experience on our website. Please visit carb-x.org/legal/ for more information. By clicking “Ok”, you consent to the use of all cookies.OkI do not consent